It is well documented that CPE receptors CLDN-3, -4, and/or -7 are abnormally regulated in many tumor types including prostate cancer [15,17,18,19,20,48], which also was confirmed for the used 0840 and 0846 cell lines [49]. This evidence concerns the gene CLDN4 and prostate carcinoma.